About Us:
Structure Therapeutics develops life‐changing medicines for patients using advanced structure‐based and computational drug discovery technology. The company’s platform combines the latest advancements in visualization of molecular interactions, computational chemistry, and data integration to design orally available, superior small molecule medicines that overcome current limitations of biologic and peptide drugs. We are advancing a clinical‐stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic, and pulmonary conditions.
Structure Therapeutics is led by an experienced group of international drug innovators and financed by top-tier global life sciences investors. The company completed an initial public offering (IPO) in February 2023. With offices in California and Shanghai, Structure Therapeutics has the benefit of being at the center of life science innovation in both the US and China and capitalizing on the strengths of each geographic location.
Position Summary:
The Associate Scientist / Scientist of DMPK will be responsible for DMPK especially in bioanalytical method development and sample analysis for Structure Therapeutics’ small molecule projects. An individual with in-depth knowledge and expertise in small molecule bioanalysis is essential. She/he will collaborate cross-functional teams to develop bioanalytical method and deliver sample analysis result to support projects progression.
Job Responsibilities:
- Proficient in the use and maintenance of LC-MS/MS
- Responsible for the LC-MS/MS method development, optimization and qualification
- Responsible for the bioanalysis in various biological matrix samples
- Responsible for data processing, analysis, report and troubleshooting
- Track DMPK assays
- Collaborate with other functions such as Biology, Chemistry, Toxicology, Regulatory and Clinical etc. to support drug discovery and development
- Effectively manage interaction with external CROs to ensure high quality and on-time execution of ADME studies
Qualifications:
- Bachelor’s degree or above in DMPK, analytical chemistry, organic chemistry or life science, with 3-5 years working experience in bioanalytical.
- Rich experience in small molecule and peptide sample bioanalysis
- Experience in handling non-rule of five small molecule sample analysis
- Experience in handling sample analysis with multiple chiral centers
- Experience in handling molecules with unstable and back-conversion (from metabolite) properties
- Experience in method development and method validation in support TK and human PK
- Familiar with bioanalytical guidance.
- Excellent verbal and written communication skills.
- Written and verbal fluency in English is preferred.
- Good interpersonal and teamwork skills
Skills Required
- Bachelor's degree or above in DMPK, analytical chemistry, organic chemistry or life science
- 3-5 years working experience in bioanalytical
- Experience in small molecule and peptide sample bioanalysis
- Experience in handling non-rule of five small molecule sample analysis
- Experience in handling sample analysis with multiple chiral centers
- Experience in handling molecules with unstable and back-conversion properties
- Experience in method development and validation in support of TK and human PK
- Familiar with bioanalytical guidance
- Excellent verbal and written communication skills
- Written and verbal fluency in English
- Good interpersonal and teamwork skills
What We Do
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, Structure Therapeutics has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world.
